IGF1-LR3 - Hemi Pharma

Long(R3)-IGF-I, first described by Francis et al. in 1992, is a lab-engineered variant of insulin-like growth factor with enhanced potency and prolonged biological action. It shows reduced affinity for IGF-binding proteins, thereby enhancing tissue availability. In the bodybuilding world, it’s valued for increasing lean mass and pumps. Unlike growth hormone, it doesn’t significantly promote thermogenesis. The compound's legal status remains ambiguous, as it was never developed into a formal pharmaceutical.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about IGF1-LR3 by Hemi Pharma, consult with your doctor or healthcare professional.